Arvinas, Inc. (ARVN) vs NeoGenomics, Inc. (NEO)
A side-by-side comparison of Arvinas, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARVN
Arvinas, Inc.
$7.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NEO
NeoGenomics, Inc.
$16.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ARVN vs NEO
growth of $100 · dividends reinvested · last 8yARVN -53.5% (-9.1%/yr)NEO +25.3% (+2.9%/yr)NEO compounded faster over this window
ARVN NEO
ARVN vs NEO: by the numbers
- •ARVN is the larger company ($472M vs $424M market cap).
- •ARVN is profitable (2.94% net margin) while NEO runs a net loss (-6.77%).
- •ARVN grew revenue faster over the past five years (72.38% vs 9.41% CAGR).
Metrics side by side
Valuation
| Metric | ARVN | NEO |
|---|---|---|
| P/E ratio | 45.69 | N/A |
| Forward P/E | N/A | 90.32 |
| P/S ratio | 1.49 | 0.55 |
| P/B ratio | 0.84 | 0.54 |
Profitability
| Metric | ARVN | NEO |
|---|---|---|
| Gross margin | 96.43% | 42.92% |
| Operating margin | -43.75% | -8.63% |
| Net margin | 2.94% | -6.77% |
| ROE | 1.65% | -6.60% |
| ROIC | -2.19% | -5.29% |
Growth (annualized)
| Metric | ARVN | NEO |
|---|---|---|
| Revenue CAGR (5Y) | 72.38% | 9.41% |
| Total return CAGR (5Y) | -38.16% | -15.14% |
Frequently asked
- Which has grown faster, ARVN or NEO?
- Over the past five years, ARVN grew revenue faster — ARVN at a 72.38% CAGR versus NEO at 9.41%.
- Is ARVN or NEO more profitable?
- ARVN runs the higher net margin — ARVN at 2.94% versus NEO at -6.77%.
- How have ARVN and NEO total returns compared?
- Over the past 5 years, ARVN delivered -38.16% and NEO delivered -15.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arvinas P/E ratioArvinas ROENeoGenomics ROEArvinas operating marginNeoGenomics operating marginArvinas revenue growthNeoGenomics revenue growthArvinas free cash flowNeoGenomics free cash flow
Arvinas & NeoGenomics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.